Award Number: W81XWH-10-1-0810

TITLE: Adaptive Disclosure: A Combat-Specific PTSD Treatment

PRINCIPAL INVESTIGATOR: Brett Litz, Ph.D.

CONTRACTING ORGANIZATION: Boston VA Research Institute
                            Boston, MA 02130

REPORT DATE: October 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
               Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                          Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Adaptive Disclosure: A Combat-Specific PTSD Treatment

Brett Litz, Ph.D.
Maria Steenkamp, Ph.D.

Brett.litz@va.gov; maria.steenkamp2@va.gov

Boston VA Research Institute
Boston, MA 02130

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for Public Release; Distribution Unlimited

Many service members exposed to combat and operational stressors develop posttraumatic stress disorder (PTSD). Evidence-based interventions for treating PTSD, however, were not developed for military trauma and thus may be suboptimal for this population. This study compares Adaptive Disclosure, an intervention for Marines and Sailors with PTSD stemming from deployment experiences, to an empirically supported PTSD treatment. The report details the third year of work on this trial in which we completed all legal/regulatory hurdles and began recruitment. The Boston team has principally been involved in conducting pre- and post-treatment psychosocial assessments that will be used to determine treatment efficacy.

Active-duty, Marine Corps, Posttraumatic stress disorder, Cognitive Therapy
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>4</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>4</td>
</tr>
<tr>
<td>Conclusion</td>
<td>5</td>
</tr>
<tr>
<td>References</td>
<td>5</td>
</tr>
<tr>
<td>Appendices</td>
<td>5</td>
</tr>
<tr>
<td>Supporting Data</td>
<td>n/a</td>
</tr>
</tbody>
</table>
INTRODUCTION:
More than 2 million U.S. troops have served in the wars in Afghanistan and Iraq. Findings from epidemiologic studies of infantry troops in the early stages of the wars suggest that 10-18% of combat troops experience deployment-related psychological health problems, such as posttraumatic stress disorder (PTSD; e.g., Hoge et al., 2004; see Litz & Schlenger, 2009). Once service members and new Veterans develop sustained mental health problems related to combat and operational stress, many are at risk to remain chronic across the lifespan (e.g., Kessler et al., 1995; Kulka et al., 1990; Prigerson et al., 2001). Thus, primary and secondary prevention of PTSD is a critical challenge for the military and the VA (e.g., Litz & Bryant, 2009). We have developed a novel intervention, Adaptive Disclosure (AD), to address these needs. AD is a hybrid and extension of evidence-informed cognitive-behavioral therapy strategies packaged and sequenced to target the three high base-rate combat and operational traumas, namely, life-threat trauma, loss (principally traumatic loss), and experiences that produce inner moral conflict (Steenkamp et al., 2011). AD employs a Prolonged Exposure (PE) strategy (imaginal emotional processing of an event) and cognitive-therapy-based techniques used in Cognitive Processing Therapy (CPT), but also includes gestalt-therapy techniques designed to target loss and moral injury. In our open pilot trial, we demonstrated treatment acceptability among Marines and large reductions in PTSD and comorbid symptoms. The primary objective of the current randomized control non-inferiority trial is to determine whether AD is as least as effective as CPT, cognitive only version (CPT-C), in terms of its impact on deployment-related psychological health problems (specifically PTSD and depression) and functioning.

BODY:
Preparatory Phase (Months 1 – 6)
- Regulatory Review and IRB Approval (Months 1-6): All necessary IRB approvals have been obtained.
- Database Development (Months 4 – 6): A study database has been established.
- Hire and Train Study Personnel (Months 1-6): All necessary hiring, credentialing, training, and certification of study personnel is complete.
- Miscellaneous Preparatory Tasks (Months 1-6): All miscellaneous preparatory activities have been successfully completed.

Patient Recruitment & Enrollment (Months 7 – 36): Data collection is ongoing. To date, the Boston site has conducted 62 pre-treatment assessments, and 14 post-treatment assessments (76 total). No adverse events have occurred. These assessments are audio-recorded and a random subsample has been sent to Dr. Matt Gray, University of Wyoming, for adherence monitoring. We are providing ongoing therapy supervision to study therapists. We are also receiving and storing deidentified data from San Diego.

Follow-Up Data Collection & Patient Closeout (Months 37 - 42): N/A

Data Analysis & Report Writing, Dissemination (Months 43-48): N/A

KEY RESEARCH ACCOMPLISHMENTS: We have completed all legal and regulatory hurdles and are currently enrolling participants in this protocol.

REPORTABLE OUTCOMES: None in this period.
CONCLUSION: Due to unforeseen and uncontrollable circumstances, this project was significantly delayed. The recruitment is now underway, and the Boston site is actively assessing study participants.

REFERENCES:


APPENDICES: None